968 related articles for article (PubMed ID: 30710469)
1. International Consensus Guidelines for the Optimal Use of the Polymyxins: Endorsed by the American College of Clinical Pharmacy (ACCP), European Society of Clinical Microbiology and Infectious Diseases (ESCMID), Infectious Diseases Society of America (IDSA), International Society for Anti-infective Pharmacology (ISAP), Society of Critical Care Medicine (SCCM), and Society of Infectious Diseases Pharmacists (SIDP).
Tsuji BT; Pogue JM; Zavascki AP; Paul M; Daikos GL; Forrest A; Giacobbe DR; Viscoli C; Giamarellou H; Karaiskos I; Kaye D; Mouton JW; Tam VH; Thamlikitkul V; Wunderink RG; Li J; Nation RL; Kaye KS
Pharmacotherapy; 2019 Jan; 39(1):10-39. PubMed ID: 30710469
[TBL] [Abstract][Full Text] [Related]
2. Framework for optimisation of the clinical use of colistin and polymyxin B: the Prato polymyxin consensus.
Nation RL; Li J; Cars O; Couet W; Dudley MN; Kaye KS; Mouton JW; Paterson DL; Tam VH; Theuretzbacher U; Tsuji BT; Turnidge JD
Lancet Infect Dis; 2015 Feb; 15(2):225-34. PubMed ID: 25459221
[TBL] [Abstract][Full Text] [Related]
3. International consensus recommendations for the use of prolonged-infusion beta-lactam antibiotics: Endorsed by the American College of Clinical Pharmacy, British Society for Antimicrobial Chemotherapy, Cystic Fibrosis Foundation, European Society of Clinical Microbiology and Infectious Diseases, Infectious Diseases Society of America, Society of Critical Care Medicine, and Society of Infectious Diseases Pharmacists: An executive summary.
Hong LT; Downes KJ; FakhriRavari A; Abdul-Mutakabbir JC; Kuti JL; Jorgensen S; Young DC; Alshaer MH; Bassetti M; Bonomo RA; Gilchrist M; Jang SM; Lodise T; Roberts JA; Tängdén T; Zuppa A; Scheetz MH
Pharmacotherapy; 2023 Aug; 43(8):736-739. PubMed ID: 37615244
[TBL] [Abstract][Full Text] [Related]
4. International consensus recommendations for the use of prolonged-infusion beta-lactam antibiotics: Endorsed by the American College of Clinical Pharmacy, British Society for Antimicrobial Chemotherapy, Cystic Fibrosis Foundation, European Society of Clinical Microbiology and Infectious Diseases, Infectious Diseases Society of America, Society of Critical Care Medicine, and Society of Infectious Diseases Pharmacists.
Hong LT; Downes KJ; FakhriRavari A; Abdul-Mutakabbir JC; Kuti JL; Jorgensen S; Young DC; Alshaer MH; Bassetti M; Bonomo RA; Gilchrist M; Jang SM; Lodise T; Roberts JA; Tängdén T; Zuppa A; Scheetz MH
Pharmacotherapy; 2023 Aug; 43(8):740-777. PubMed ID: 37615245
[TBL] [Abstract][Full Text] [Related]
5. To B or not to B, that is the question: is it time to replace colistin with polymyxin B?
Kassamali Z; Danziger L
Pharmacotherapy; 2015 Jan; 35(1):17-21. PubMed ID: 25346395
[TBL] [Abstract][Full Text] [Related]
6. Response to comment on "International consensus recommendations for the use of prolonged-infusion β-lactams endorsed by the American College of Clinical Pharmacy (ACCP), the British Society for Antimicrobial Chemotherapy (BSAC), the Cystic Fibrosis Foundation (CFF), the European Society of Clinical Microbiology and Infectious Diseases (ESCMID), the Infectious Diseases Society of American (IDSA), the Society of Critical Care Medicine (SCCM), and the Society of Infectious Diseases Pharmacists".
Hong LT; Downes KJ; FakhriRavari A; Abdul-Mutakabbir JC; Kuti JL; Jorgensen S; Young DC; Alshaer MH; Bassetti M; Bonomo RA; Gilchrist M; Jang SM; Lodise T; Roberts JA; Tängdén T; Zuppa A; Scheetz MH
Pharmacotherapy; 2024 Feb; 44(2):208-209. PubMed ID: 38362632
[No Abstract] [Full Text] [Related]
7. "Comment on 'international consensus recommendations for the use of prolonged-infusion β-lactams endorsed by the American College of Clinical Pharmacy (ACCP), the British Society for Antimicrobial Chemotherapy (BSAC), the Cystic Fibrosis Foundation (CFF), the European Society of Clinical Microbiology and Infectious Diseases (ESCMID), the infectious diseases Society of American (IDSA), the Society of Critical Care Medicine (SCCM), and the Society of Infectious Diseases Pharmacists'".
Espinoza Cobeñas CA
Pharmacotherapy; 2024 Feb; 44(2):207. PubMed ID: 38362633
[No Abstract] [Full Text] [Related]
8. An update on the arsenal for multidrug-resistant Acinetobacter infections: polymyxin antibiotics.
Kassamali Z; Jain R; Danziger LH
Int J Infect Dis; 2015 Jan; 30():125-32. PubMed ID: 25461655
[TBL] [Abstract][Full Text] [Related]
9. Rational use of intravenous polymyxin B and colistin: A review.
Zakuan ZD; Suresh K
Med J Malaysia; 2018 Oct; 73(5):351-359. PubMed ID: 30350826
[TBL] [Abstract][Full Text] [Related]
10. Colistin and polymyxin B in critical care.
Michalopoulos A; Falagas ME
Crit Care Clin; 2008 Apr; 24(2):377-91, x. PubMed ID: 18361952
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetics/pharmacodynamics of colistin and polymyxin B: are we there yet?
Tran TB; Velkov T; Nation RL; Forrest A; Tsuji BT; Bergen PJ; Li J
Int J Antimicrob Agents; 2016 Dec; 48(6):592-597. PubMed ID: 27793510
[TBL] [Abstract][Full Text] [Related]
12. Polymyxins for CNS infections: Pharmacology and neurotoxicity.
Velkov T; Dai C; Ciccotosto GD; Cappai R; Hoyer D; Li J
Pharmacol Ther; 2018 Jan; 181():85-90. PubMed ID: 28750947
[TBL] [Abstract][Full Text] [Related]
13. Polymyxin B: similarities to and differences from colistin (polymyxin E).
Kwa A; Kasiakou SK; Tam VH; Falagas ME
Expert Rev Anti Infect Ther; 2007 Oct; 5(5):811-21. PubMed ID: 17914915
[TBL] [Abstract][Full Text] [Related]
14. Clinical translation of polymyxin-based combination therapy: Facts, challenges and future opportunities.
Zhang X; Guo F; Shao H; Zheng X
J Infect; 2017 Feb; 74(2):118-130. PubMed ID: 27998750
[TBL] [Abstract][Full Text] [Related]
15. Contemporary assessment of antimicrobial susceptibility testing methods for polymyxin B and colistin: review of available interpretative criteria and quality control guidelines.
Gales AC; Reis AO; Jones RN
J Clin Microbiol; 2001 Jan; 39(1):183-90. PubMed ID: 11136768
[TBL] [Abstract][Full Text] [Related]
16. The use of intravenous and aerosolized polymyxins for the treatment of infections in critically ill patients: a review of the recent literature.
Falagas ME; Kasiakou SK; Tsiodras S; Michalopoulos A
Clin Med Res; 2006 Jun; 4(2):138-46. PubMed ID: 16809407
[TBL] [Abstract][Full Text] [Related]
17. Polymyxin combinations: pharmacokinetics and pharmacodynamics for rationale use.
Bergen PJ; Bulman ZP; Saju S; Bulitta JB; Landersdorfer C; Forrest A; Li J; Nation RL; Tsuji BT
Pharmacotherapy; 2015 Jan; 35(1):34-42. PubMed ID: 25630411
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetics and pharmacodynamics of 'old' polymyxins: what is new?
Bergen PJ; Landersdorfer CB; Zhang J; Zhao M; Lee HJ; Nation RL; Li J
Diagn Microbiol Infect Dis; 2012 Nov; 74(3):213-23. PubMed ID: 22959816
[TBL] [Abstract][Full Text] [Related]
19. Rescuing the Last-Line Polymyxins: Achievements and Challenges.
Nang SC; Azad MAK; Velkov T; Zhou QT; Li J
Pharmacol Rev; 2021 Apr; 73(2):679-728. PubMed ID: 33627412
[TBL] [Abstract][Full Text] [Related]
20. Clinical considerations for optimal use of the polymyxins: A focus on agent selection and dosing.
Pogue JM; Ortwine JK; Kaye KS
Clin Microbiol Infect; 2017 Apr; 23(4):229-233. PubMed ID: 28238870
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
